KardiaMobile 6L can be used to measure QT duration in COVID-19 patients - Cardiac Rhythm News

KardiaMobile 6L, which it describes in a press release as the world’s only six lead personal ECG.

Artificial Intelligence–Enabled Assessment of the Heart Rate Corrected QT Interval Using a Mobile Electrocardiogram Device

AliveCor gains US FDA clearance for KardiaMobile 6L to calculate patients' QTc interval - Medical Device News by Guided Solutions

PDF) Feasibility of using KardiaMobile-L6 for QT interval monitoring during the early phase of the COVID-19 pandemic in critical care patients

RApid Throughput Screening for Asymptomatic COVID-19 Infection With an Electrocardiogram: A Prospective Observational Study - Mayo Clinic Proceedings: Digital Health

What's the difference between KardiaMobile and KardiaMobile 6L?

How To Measure and Assess a Long QT Interval

AliveCor and Thomas Jefferson University Hospital Partner to Evaluate KardiaMobile 6L for QT Prolongation Screening in Patients Treated for Opioid Use Disorder

COVID-19 Archives - Cardiac Rhythm News

2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals - Varma - 2021 - Annals of Noninvasive Electrocardiology - Wiley Online Library

Implementation of a fully remote randomized clinical trial with cardiac monitoring

AliveCor (@AliveCor) / X

Manual QT interval measurement with a smartphone-operated single-lead ECG versus 12-lead ECG: a within-patient diagnostic validation study in primary care

ECG register with KardiaMobile-6L.